Get the Stockscreener App
4.92
3.72%
-0.19
Pre-market:
5.03
0.11
+2.24%
Abcellera Biologics Inc stock is traded at $4.92, with a volume of 4.11M.
It is down -3.72% in the last 24 hours and up +36.29% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$5.11
Open:
$5.15
24h Volume:
4.11M
Relative Volume:
0.70
Market Cap:
$1.47B
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-9.4615
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
-4.47%
1M Performance:
+36.29%
6M Performance:
+49.09%
1Y Performance:
+50.92%
1-Day Range:
$4.8912
$5.1868
1-Week Range:
$4.67
$5.36
52-Week Range:
$1.8906
$5.82
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.92 | 1.53B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
Why AbCellera Biologics Inc. stock is on top investor watchlistsEntry Plan for Oversold Reversal Stocks Released - beatles.ru
How strong is AbCellera Biologics Inc. company’s balance sheetChart Pattern Trend Scanner With Low Risk - jammulinksnews.com
Does AbCellera Biologics Inc. stock perform well during market downturnsMaximize gains with proven stock analysis - jammulinksnews.com
What is the dividend policy of AbCellera Biologics Inc. stockStay informed with daily expert analysis - jammulinksnews.com
What are analysts’ price targets for AbCellera Biologics Inc. in the next 12 monthsLow Risk Alerts With Proven Results - jammulinksnews.com
When is AbCellera Biologics Inc. stock expected to show significant growthSuperior return velocity - jammulinksnews.com
Should I hold or sell AbCellera Biologics Inc. stock in 2025Get alerts on high-potential stock breakouts - jammulinksnews.com
How does AbCellera Biologics Inc. compare to its industry peersHarness the power of proven investment plans - jammulinksnews.com
Is AbCellera Biologics Inc. stock overvalued or undervaluedGet exclusive market analysis for investors - jammulinksnews.com
How does AbCellera Biologics Inc. generate profit in a changing economyStay ahead with daily expert stock picks - jammulinksnews.com
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN
Why AbCellera Biologics Inc. stock attracts strong analyst attentionBreakout Momentum Alerts - metal.it
AbCellera’s AI Antibody Platform Excites Investors, Despite Big Risks - Finimize
Is AbCellera Biologics Inc. a good long term investmentConsistent double returns - PrintWeekIndia
AbCellera Biologics Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia
Is AbCellera Biologics Inc. stock a good hedge against inflationSkyrocketing profit margins - jammulinksnews.com
What analysts say about AbCellera Biologics Inc. stockRapid wealth creation - PrintWeekIndia
What drives AbCellera Biologics Inc. stock priceExponential return rates - Autocar Professional
AbCellera: Just Another Biotech Stock (NASDAQ:ABCL) - Seeking Alpha
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot - MSN
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? - MSN
ABCL.O Surges 15.5% Intraday: A Deep Dive Into the Drivers Behind the Sharp Move - AInvest
ABCL Stock Surge: Opportunity or Caution? - StocksToTrade
AbCellera Biologics Stock (ABCL) Opinions on Recent Price Surge - Nasdaq
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday - Benzinga
AbCellera Biologics (ABCL) Surges 18.75% Intraday: What’s Fueling This Biotech Breakout? - AInvest
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):